Drugs in Dev.
Neurology
Discovery
Canada 
Details : The project included rational design of novel candidates, in-silico 3D docking studies on the 5HT2A serotonin receptor, and screening of the candidates in an in-vitro platform, to assess the receptor activation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : McGill University
Deal Size : Undisclosed
Deal Type : Partnership
Details : Neurasic’s potential drug therapy targets acid-sensing ion channels (ASICs), a gene family of neuronal receptors activated by protons that play a role in multiple neurological disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : McGill University
Deal Size : Undisclosed
Deal Type : Partnership

Details : Data showing precision selectivity for neurotoxic TDP-43 and alpha-synuclein publishes in Neurology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 09, 2020
